Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.